Cite
HARVARD Citation
Jabbour, E. et al. (2018). Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet. 5 (12), pp. e618-e627. [Online].